Gold-nanofève surface-enhanced Raman spectroscopy visualizes hypotaurine as a robust anti-oxidant consumed in cancer survival

Megumi Shiota, Masayuki Naya, Takehiro Yamamoto, +20

Nature Communications

Glutaminolysis‐related genes determine sensitivity to xCT‐targeted therapy in head and neck squamous cell carcinoma

Shogo Okazaki, Kiyoko Umene, Juntaro Yamasaki, +11

Cancer Science

Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells

Shogo Okazaki, Subaru Shintani, Yuki Hirata, +7

Oncotarget

Drug LibrarySynthetic LethalityRedox BiologyOxidative StressMedicinal Chemistry +16

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)

Kohei Shitara, Toshihiko Doi, Osamu Nagano, +12

Gastric Cancer

Gastrointestinal OncologyMedicineCancer ManagementGastroenterologyPathology +5

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer

Kohei Otsubo, Kaname Nosaki, Chiyo K. Imamura, +19

Cancer Science

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease

Motoyasu Kato, Takehito Shukuya, Fumiyuki Takahashi, +11

BMC Cancer

Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells

Isao Kobayashi, Fumiyuki Takahashi, Fariz Nurwidya, +13

Biochemical and Biophysical Research Communications

MedicineCrucial RoleStem Cell ResearchCancer BiologyTumor Suppressor +6

Epidermal growth factor receptor promotes glioma progression by regulating <scp>xCT</scp> and GluN2B‐containing <i>N</i>‐methyl‐<scp>d</scp>‐aspartate–sensitive glutamate receptor signaling

Kentaro Suina, Kenji Tsuchihashi, Juntaro Yamasaki, +12

Cancer Science

Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT‐targeted therapy

Yuji Otsuki, Juntaro Yamasaki, Kentaro Suina, +4

Cancer Science

MEK inhibition suppresses metastatic progression of <i>KRAS</i>‐mutated gastric cancer

Juntaro Yamasaki, Yuki Hirata, Yuji Otsuki, +7

Cancer Science